The bisphosphonate zoledronate prevents vertebral bone loss in mature estrogen-deficient rats as assessed by micro-computed tomography
The effect of long-term treatment with the bisphosphonate zoledronate on vertebral bone architecture was investigated in estrogen-deficient mature rats. 4-month-old rats were ovariectomized and development of cancellous osteopenia was assessed after 1 year. The change of bone architectural parameter...
Main Author: | Glatt M. |
---|---|
Format: | Article |
Language: | English |
Published: |
AO Research Institute Davos
2001-01-01
|
Series: | European Cells & Materials |
Online Access: | http://www.ecmjournal.org/journal/papers/vol001/vol001a03.php |
Similar Items
-
Cepharanthine Prevents Estrogen Deficiency-Induced Bone Loss by Inhibiting Bone Resorption
by: Chen-he Zhou, et al.
Published: (2018-03-01) -
Bones, breasts, and bisphosphonates: rationale for the use of zoledronic acid in advanced and early breast cancer
by: Allan Lipton
Published: (2011-03-01) -
Repression of osteoblast maturation by ERRα accounts for bone loss induced by estrogen deficiency.
by: Marlène Gallet, et al.
Published: (2013-01-01) -
Iron accumulation deteriorated bone loss in estrogen-deficient rats
by: Lu-lin Liu, et al.
Published: (2021-08-01) -
Safety of Intravitreal Zoledronic Acid, an Anti-angiogenic Bisphosphonate, in a Rat Model
by: Ramin Nourinia, et al.
Published: (2014-01-01)